• / Free eNewsletters & Magazine
  • / My Account
Home>DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

10/03/2017

DR. REDDY'S INVESTOR ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $100,000 In Dr. Reddy's Laboratories Limited To Contact The Firm

Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Dr. Reddy's Laboratories Limited (“Dr. Reddy's” or the “Company”) (NYSE:RDY) of the October 24, 2017 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.

If you invested in Dr. Reddy's stock or options between June 17, 2015 and August 10, 2017 and would like to discuss your legal rights, click here : www.faruqilaw.com/RDY. There is no cost or obligation to you.

You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com .

The lawsuit has been filed in the U.S. District Court for the District of New Jersey on behalf of all those who purchased Dr. Reddy's securities between June 17, 2015 and August 10, 2017 (the “Class Period”). The case, Critchley v. Dr. Reddy’s Laboratories Limited et al, No. 3:17-cv-06436 was filed on August 25, 2017.

The lawsuit focuses on whether the Company and its executives violated federal securities laws by making false and/or misleading statements and/or failing to disclose that: (1) Dr. Reddy's lacked an effective corporate quality system; and (2) as a result, Dr. Reddy's public statements were materially false and misleading.

Specifically, on August 10, 2017, Dr. Reddy's published a letter disclosing that the Regulatory Authority of Germany (Regierung von Oberbayern) sent notice to Dr. Reddy’s wholly-owned subsidiary, betapharm Arzneimittel GmbH, that one of the Company’s plants lost its Good Manufacturing Practices compliance certificate.

On this news, Dr. Reddy's share price fell from $32.25 per share on August 9, 2017 to a closing price of $30.33 on August 10, 2017 —a $1.92 or a 5.95% drop.

©2017 Morningstar Advisor. All right reserved.